|
| | Lumacaftor (VX-809) Basic information |
| Product Name: | Lumacaftor (VX-809) | | Synonyms: | 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxaMido)-3-Methylpyridin-2-yl)benzoic acid;VRT 826809;3-(6-{[1-(2,2-Difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)be;VX 809, >=98%;VX-809 (LUMACAFTOR);VX 809;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid;3-(6-{[1-(2,2-Difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl;VX-809 + IVACAFTOR | | CAS: | 936727-05-8 | | MF: | C24H18F2N2O5 | | MW: | 452.41 | | EINECS: | | | Product Categories: | Inhibitors;VX-809 | | Mol File: | 936727-05-8.mol |  |
| | Lumacaftor (VX-809) Chemical Properties |
| Melting point | 200-205oC | | Boiling point | 653.0±55.0 °C(Predicted) | | density | 1.51 | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 3.95±0.10(Predicted) | | form | Solid | | color | White to Off-White |
| | Lumacaftor (VX-809) Usage And Synthesis |
| Uses | VX 809 is used in the stabilization of the CFTR protein used in the treatment of cystic fibrosis. | | Definition | ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fi
rosis. | | Biological Activity | vx-809 is a cftr corrector that partially restores the function of f508del-cftr. in fischer rat thyroid (frt) cells, it increases f508del-cftr maturation at ec50 of 0.1 μm, and elevates f508del-cftr–mediated chloride transport at ec50 of 0.5 μm [1]. it has no effect of other ion channels (herg), transporter (p-gp) and disease-causing mislocalized proteins (α1-antitrypsin z mutant) [1]. vx-809 stabilizes n-terminal fragment of cftr that contain msd1 by altering its protein conformation [2, 3].homozygous f508del-cftr is the most common mutation in cystic fibrosis (cf) patients, accounting for 66–70% of cf cases worldwide. in cultured human bronchial epithelial cells that are homozygous for f508del, vx-809 restored the cftr function and improved chloride and fluid transport [1]. the combination of cftr potentiators and vx-809 further improved the function of f508del-cftr [4].vx-809 has been tested in several | | target | CFTR |
| | Lumacaftor (VX-809) Preparation Products And Raw materials |
|
